Gene Silencing Therapeutics Market Report 2026

Gene Silencing Therapeutics Market Overview

• Gene Silencing Therapeutics market size has reached to $4 billion in 2025 • Expected to grow to $8.49 billion in 2030 at a compound annual growth rate (CAGR) of 16.3% • Growth Driver: Growing Focus On Personalized Medicine Fueling The Growth Of The Market Due To Increasing Demand For Targeted Genetic Treatments • Market Trend: Innovations In Kidney-Targeted Gene Silencing Technologies Advance Precision Genetic Medicine Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gene Silencing Therapeutics Market?

Gene silencing therapeutics are treatments that work by reducing, blocking, or turning off the expression of specific disease-causing genes to prevent the production of harmful proteins in the body. These therapies use advanced molecular technologies to target messenger RNA (mRNA) before defective proteins are produced. Gene silencing therapeutics are widely used in the treatment of various conditions by selectively regulating abnormal gene activity. The main technologies of gene silencing therapeutics include ribonucleic acid interference, antisense oligonucleotides, clustered regularly interspaced short palindromic repeats associated protein 9, and other technologies. Ribonucleic acid interference refers to a gene regulation mechanism that suppresses the expression of specific genes by targeting and degrading messenger RNA molecules. These therapeutics utilize delivery methods including nanoparticles, viral vectors, liposomes, and other delivery methods. The key applications of oncology, genetic disorders, infectious diseases, neurological disorders, and others, while the end-users includes hospitals, research institutes, pharmaceutical and biotechnology companies, and others.

What Is The Gene Silencing Therapeutics Market Growth Forecast?

The gene silencing therapeutics market size is expected to see rapidly grown in the next few years. It will grow to $8.49 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to advancing commercialization of gene silencing therapeutics, growing pipeline of precision genetic medicines, increasing regulatory approvals for novel gene therapies, expanding application across oncology and neurological disorders, rising adoption of personalized medicine strategies. Major trends in the forecast period include increasing adoption of RNA interference based therapeutics, growing development of antisense oligonucleotide treatment platforms, rising focus on targeted gene expression regulation for rare diseases, expansion of advanced delivery technologies for gene silencing therapeutics, increasing clinical research activity in next generation gene silencing therapies.

Global Gene Silencing Therapeutics Market Segmentation

1) By Technology: Ribonucleic Acid Interference; Antisense Oligonucleotides; Other Technologies 2) By Delivery Method: Nanoparticles; Viral Vectors; Liposomes; Other Delivery Methods 3) By Application: Oncology; Genetic Disorders; Infectious Diseases; Neurological Disorders; Other Applications 4) By End User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users Subsegments: 1) By Ribonucleic Acid Interference: Small Interfering Ribonucleic Acid Therapeutics; Short Hairpin Ribonucleic Acid Therapeutics; Micro Ribonucleic Acid Therapeutics; Dicer Substrate Small Interfering Ribonucleic Acid Therapeutics 2) By Antisense Oligonucleotides: Exon Skipping Oligonucleotides; Splice Switching Oligonucleotides; Gapmer Antisense Oligonucleotides; Phosphorothioate Oligonucleotides; Peptide Conjugated Oligonucleotides 3) By Other Technologies: Aptamer Based Gene Silencing; Zinc Finger Nuclease Technologies; Transcription Activator Like Effector Nuclease Based Gene Silencing; Messenger Ribonucleic Acid Degradation Technologies; Epigenetic Gene Silencing Technologies

What Is The Driver Of The Gene Silencing Therapeutics Market?

The growing focus on personalized medicine is expected to propel the growth of the gene silencing therapeutics market going forward. Personalized medicine refers to a healthcare approach that customizes medical treatment based on an individual’s genetic profile, biomarkers, and specific disease characteristics to enhance treatment effectiveness and clinical outcomes. The increasing focus on personalized medicine is driven by advancements in genetic and molecular profiling technologies that enable tailored treatments based on individual patient characteristics. Gene-silencing therapeutics support personalized medicine by selectively targeting disease-causing genes based on an individual’s genetic profile, enabling more precise treatment with improved effectiveness and fewer side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the gene silencing therapeutics industry.

Key Players In The Global Gene Silencing Therapeutics Market

Major companies operating in the gene silencing therapeutics market are Novartis AG; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Silence Therapeutics plc; Wave Life Sciences Ltd.; ProQR Therapeutics N.V.; Dyne Therapeutics Inc.; Stoke Therapeutics Inc.; Arbutus Biopharma Corporation; PepGen Inc.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Benitec Biopharma Inc.; ADARx Pharmaceuticals Inc.; Tune Therapeutics Inc.; Sylentis S.A.; Isarna Therapeutics GmbH; City Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Novo Nordisk; Moderna Inc.; BioNTech SE; Sanofi

Global Gene Silencing Therapeutics Market Trends and Insights

Major companies operating in the gene silencing therapeutics market are adopting advanced RNA delivery platforms, such as ligand-conjugated siRNA technologies, to improve tissue-specific targeting and enhance therapeutic precision for genetic and renal diseases. Ligand-conjugated siRNA technologies refer to specialized RNA delivery approaches that attach targeting ligands to small interfering RNA molecules to enable receptor-mediated uptake and selective gene silencing in specific tissues or cell types. For instance, in June 2025, Judo Bio, Inc., a US-based biotechnology company, launched with $100 million in Series A financing led by Atlas Venture, TCG, and Droia Ventures to advance precision genetic medicines targeting kidney diseases. The company introduced its STRIKE (Selectively Targeting RNA Into Kidney) platform, a ligand-conjugated siRNA delivery technology engineered for receptor-mediated uptake into kidney cell types, enabling selective gene silencing in renal tissues. The platform’s initial megalin-STRIKER programs are designed to deliver small interfering RNA therapeutics to proximal tubule cells in the kidney to silence mRNA expression of solute carrier proteins associated with systemic and renal diseases.

What Are Latest Mergers And Acquisitions In The Gene Silencing Therapeutics Market?

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed amount. With this acquisition, Novartis aimed to strengthen its gene silencing therapeutics pipeline by integrating DTx Pharma’s proprietary FALCON RNA delivery platform to expand the development of RNAi-based therapies for neurological and neuromuscular diseases. DTx Pharma Inc. is a US-based biotechnology company specializing in RNA-based therapeutics, particularly small interfering RNA (siRNA) technologies designed to silence disease-causing genes.

Regional Outlook

North America was the largest region in the gene silencing therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gene Silencing Therapeutics Market?

The gene silencing therapeutics market consists of revenues earned by entities by providing services such as RNA interference (RNAi) therapy development, antisense oligonucleotide therapy services, gene expression suppression solutions, target gene validation, therapeutic RNA design, drug delivery optimization, clinical development services, and precision medicine support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene silencing therapeutics market also includes sales of microfluidic delivery systems, electroporation devices, lipid nanoparticle formulation equipment, and automated nucleic acid synthesizers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gene Silencing Therapeutics Market Report 2026?

The gene silencing therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene silencing therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.